Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults

Journal of Clinical Oncology

Volumn 33, Issue 28, 2015, Pages 3152-3161

  Kasamon, Yvette L ^a   Bolaños Meade, Javier ^a   Prince, Gabrielle T ^a   Tsai, Hua Ling ^a   McCurdy, Shannon R ^a   Kanakry, Jennifer A ^a   Rosner, Gary L ^a   Brodsky, Robert A ^a   Perica, Karlo ^a   Smith, B Douglas ^a   Gladstone, Douglas E ^a   Swinnen, Lode J ^a   Showel, Margaret M ^a   Matsui, William H ^a   Huff, Carol Ann ^a   Borrello, Ivan ^a   Pratz, Keith W ^a   McDevitt, Michael A ^a   Gojo, Ivana ^a   Dezern, Amy E ^a   Shanbhag, Satish ^a   Levis, Mark J ^a   Luznik, Leo ^a   Ambinder, Richard F ^a   Fuchs, Ephraim J ^a   Jones, Richard J ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FILGRASTIM; FLUDARABINE; HLA ANTIGEN; MESNA; MYCOPHENOLATE MOFETIL; TACROLIMUS; ALKYLATING AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGE; AGED; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CONFERENCE PAPER; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HLA MATCHING; HUMAN; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; DISEASE COURSE; DISEASE FREE SURVIVAL; DONOR; GENETICS; GRAFT VS HOST DISEASE; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATIENT SELECTION; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TRANSPLANTATION CONDITIONING;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84944243087     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.4777     Document Type: Conference Paper

References (43)

1. Grewal SS, Barker JN, Davies SM, et al: Unrelated donor hematopoietic cell transplantation: Marrow or umbilical cord blood? Blood 101: 4233-4244, 2003
2. Kawase T, Morishima Y, Matsuo K, et al: High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implication for its molecular mechanism. Blood 110: 2235-2241, 2007
3. Szydlo R, Goldman JM, Klein JP, et al: Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 15: 1767-1777, 1997
4. Kanda Y, Chiba S, Hirai H, et al: Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 102: 1541-1547, 2003
5. Petersdorf EW, Gooley TA, Anasetti C, et al: Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92: 3515-3520, 1998
6. Beatty PG, Clift RA, Mickelson EM, et al: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 313: 765-771, 1985
7. Morishima Y, Sasazuki T, Inoko H, et al: The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 99: 4200-4206, 2002
8. Jones RJ: Haploidentical transplantation: Repurposing cyclophosphamide. Biol Blood Marrow Transplant 18: 1771-1772, 2012
9. Luznik L, O'Donnell PV, Fuchs EJ: Posttransplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol 39: 683-693, 2012
10. Schwartz R, Dameshek W: Drug-induced immunological tolerance. Nature 183: 1682-1683, 1959
11. Kanakry CG, Ganguly S, Zahurak M, et al: Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 5: 211ra157, 2013
12. Solomon SR, Sizemore CA, Sanacore M, et al: Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: Results of a prospective phase II trial. Biol Blood Marrow Transplant 18: 1859-1866, 2012
13. Brunstein CG, Fuchs EJ, Carter SL, et al: Alternative donor transplantation after reduced intensity conditioning: Results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 118: 282-288, 2011
14. Luznik L, O'Donnell PV, Symons HJ, et al: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14: 641-650, 2008
15. Raiola A, Dominietto A, Varaldo R, et al: Unmanipulated haploidentical BMT following nonmyeloablative conditioning and post-Transplantation CY for advanced Hodgkin's lymphoma. Bone Marrow Transplant 49: 190-194, 2014
16. Ciurea SO, Mulanovich V, Saliba RM, et al: Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18: 1835-1844, 2012
17. Kasamon YL, Luznik L, Leffell MS, et al: Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: Effect of HLA disparity on outcome. Biol Blood Marrow Transplant 16: 482-489, 2010
18. National Cancer Institute: SEER stat fact sheets: Non-Hodgkin lymphoma. http://www.seer .cancer.gov/statfacts/html/nhl.html
19. National Cancer Institute: SEER stat fact sheets: Leukemia. http://www.seer.cancer.gov/statfacts/html/leuks.html
20. Smith BD, Smith GL, Hurria A, et al: Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol 27: 2758-2765, 2009
21. Gisselbrecht C, Glass B, Mounier N, et al: Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28: 4184-4190, 2010
22. Cheson BD, Bennett JM, Kopecky KJ, et al: Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642-4649, 2003
23. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25: 579-586, 2007
24. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106: 2912-2919, 2005
25. Armand P, Kim HT, Logan BR, et al: Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 123: 3664-3671, 2014
26. Center for International Blood and Marrow Transplant Research: CIBMTR forms manual: 100 days post-HSCT data form 2100, version 1.4 (06/20/2014). http://www.cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/Documents
27. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15: 825-828, 1995
28. Filipovich AH, Weisdorf D, Pavletic S, et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11: 945-956, 2005
29. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16: 1141-1154, 1988
30. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94: 496-509, 1999
31. Zhou B, Latouche A, Rocha V, et al: Competing risks regression for stratified data. Biometrics 67: 661-670, 2011
32. Ihaka R, Gentleman R: R: A language for data analysis and graphics. J Comput Graph Stat 5: 299-314, 1996
33. Alyea EP, Kim HT, Ho V, et al: Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105: 1810-1814, 2005
34. Estey E, de Lima M, Tibes R, et al: Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 109: 1395-1400, 2007
35. Kollman C, Howe CW, Anasetti C, et al: Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: The effect of donor age. Blood 98: 2043-2051, 2001
36. Muffly LS, Boulukos M, Swanson K, et al: Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. Biol Blood Marrow Transplant 19: 429-434, 2013
37. Klepin HD, Geiger AM, Tooze JA, et al: Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood 121: 4287-4294, 2013
38. McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 28: 1878-1887, 2010
39. Lim Z, Brand R, Martino R, et al: Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 28: 405-411, 2010
40. Sorror ML, Sandmaier BM, Storer BE, et al: Long-Term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 306: 1874-1883, 2011
41. Aoudjhane M, Labopin M, Gorin NC, et al: Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19: 2304-2312, 2005
42. Zeidan AM, Forde PM, Symons H, et al: HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20: 314-318, 2014
43. Chen YB, Li S, Lane AA, et al: Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 20: 2042-2048, 2014